Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedFeb 25, 2026
DataAggregated Company Financials
Companies21
  • 7D-16.8%
  • 3M-20.4%
  • 1Y-56.2%
  • YTD-22.3%

Over the last 7 days, the Healthcare industry has dropped 17%, driven by Novo Nordisk declining 21%. The industry has fallen 56% in the last year. Earnings are forecast to grow by 4.4% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 25 Feb 2026DKK 1.5tDKK 447.7bDKK 131.0b18.7x11.6x3.4x
Fri, 23 Jan 2026DKK 2.3tDKK 453.8bDKK 136.9b18.7x16.5x5x
Sun, 21 Dec 2025DKK 1.9tDKK 453.8bDKK 136.9b16.9x13.7x4.1x
Tue, 18 Nov 2025DKK 1.9tDKK 454.1bDKK 137.0b17.1x13.8x4.2x
Thu, 16 Oct 2025DKK 2.1tDKK 447.6bDKK 141.7b18.3x15x4.7x
Sat, 13 Sep 2025DKK 2.0tDKK 447.3bDKK 141.7b19.9x14.4x4.6x
Mon, 11 Aug 2025DKK 1.9tDKK 434.8bDKK 132.5b28.7x14.2x4.3x
Wed, 09 Jul 2025DKK 2.5tDKK 423.0bDKK 124.5b30.7x19.7x5.8x
Fri, 06 Jun 2025DKK 2.6tDKK 423.7bDKK 124.6b30.8x20.7x6.1x
Sun, 04 May 2025DKK 2.5tDKK 409.3bDKK 121.3b23x20.6x6.1x
Tue, 01 Apr 2025DKK 2.6tDKK 409.5bDKK 121.3b23.1x21.1x6.2x
Thu, 27 Feb 2025DKK 3.4tDKK 410.0bDKK 121.4b28.8x28x8.3x
Sat, 25 Jan 2025DKK 3.3tDKK 387.4bDKK 111.3b29.4x29.8x8.6x
Mon, 23 Dec 2024DKK 3.1tDKK 387.4bDKK 111.3b28.7x28.2x8.1x
Wed, 20 Nov 2024DKK 3.8tDKK 387.3bDKK 111.3b32.1x33.8x9.7x
Fri, 18 Oct 2024DKK 4.2tDKK 372.1bDKK 107.2b37.3x39.2x11.3x
Sun, 15 Sep 2024DKK 4.7tDKK 372.0bDKK 107.1b36x43.8x12.6x
Tue, 13 Aug 2024DKK 4.6tDKK 370.3bDKK 107.0b36.1x42.6x12.3x
Thu, 11 Jul 2024DKK 4.9tDKK 355.3bDKK 106.2b35.6x46.3x13.9x
Sat, 08 Jun 2024DKK 4.9tDKK 355.3bDKK 106.2b36.2x46.5x13.9x
Mon, 06 May 2024DKK 4.3tDKK 354.8bDKK 106.4b33.9x40.9x12.3x
Wed, 03 Apr 2024DKK 4.5tDKK 341.2bDKK 99.6b38.4x44.7x13.1x
Fri, 01 Mar 2024DKK 4.2tDKK 340.1bDKK 98.9b38.2x42.9x12.5x
Sun, 28 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b34.7x42x11.8x
Tue, 26 Dec 2023DKK 3.6tDKK 320.4bDKK 90.0b32.8x40.2x11.3x
Thu, 23 Nov 2023DKK 3.6tDKK 320.5bDKK 90.0b32.7x40.4x11.4x
Sat, 21 Oct 2023DKK 3.5tDKK 305.5bDKK 82.2b27.8x42.6x11.5x
Mon, 18 Sep 2023DKK 3.5tDKK 305.5bDKK 82.2b36.6x42.9x11.5x
Wed, 16 Aug 2023DKK 3.3tDKK 301.3bDKK 81.0b40x40.9x11x
Fri, 14 Jul 2023DKK 2.9tDKK 286.9bDKK 75.4b38.3x38x10x
Sun, 11 Jun 2023DKK 3.0tDKK 287.1bDKK 75.5b40x39.9x10.5x
Tue, 09 May 2023DKK 3.2tDKK 284.0bDKK 74.5b40.3x42.5x11.1x
Thu, 06 Apr 2023DKK 3.0tDKK 272.4bDKK 68.5b39.4x43.5x10.9x
Sat, 04 Mar 2023DKK 2.8tDKK 292.6bDKK 69.2b39.4x40.7x9.6x
Price to Earnings Ratio

40.7x


Total Market Cap: DKK 2.8tTotal Earnings: DKK 69.2bTotal Revenue: DKK 292.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 32.8x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 11.6x which is lower than its 3-year average PE of 32.8x.
  • The 3-year average PS ratio of 9.3x is higher than the industry's current PS ratio of 3.4x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 24% per year over the last three years.
  • Revenues for these companies have grown 15% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-7.74%
Healthcare-16.81%
Healthcare Services5.00%
Medical Equipment-1.30%
Biotech-4.70%
Healthtech-5.01%
Life Sciences-7.76%
Pharma-20.20%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 392x.
    • Analysts are expecting annual earnings growth of 85.3%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 85% over the next 5 years.
  • This is better than its past earnings decline of 100% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 21% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
COLO B ColoplastDKK 488.800.8%
+DKK 923.2m		-39.2%PE27.6x
BAVA Bavarian NordicDKK 196.751.5%
+DKK 232.5m		13.2%PE6.2x
SMSMED Scandinavian Medical SolutionsDKK 3.785.0%
+DKK 5.0m		-29.7%PE4042.6x
PEG Pharma Equity GroupDKK 0.0982.5%
+DKK 2.9m		-29.9%PB3x
STRAP Strategic PartnersDKK 624.0011.0%
+DKK 2.6m		-21.2%PB1.4x

Latest News

NOVO B
DKK 243.65
Novo Nordisk
7D
-21.4%
1Y
-62.9%
ZEAL
DKK 365.20
Zealand Pharma
7D
-5.9%
1Y
-49.2%

ZEAL: Positive Immunology Data And Metabolic Partnership Will Support Future Upside

Analysts have trimmed their price target on Zealand Pharma by DKK 5 to reflect updated assumptions for revenue growth, profit margins and a higher forward P/E. They have kept the overall discount rate broadly in line with prior views.
GMAB
DKK 1,851.50
Genmab
7D
-5.2%
1Y
13.1%
AMBU B
DKK 78.45
Ambu
7D
-3.9%
1Y
-42.7%

AMBU B: Share Buybacks And Margin Discipline Will Support Future Upside

The analyst price target for Ambu has been trimmed by DKK 1 to DKK 138, as analysts factor in slightly more cautious assumptions on growth, margins and discount rates following recent price target adjustments, such as the DKK 12 cut highlighted by JPMorgan. Analyst Commentary Bullish analysts remain focused on how Ambu can justify its current valuation through consistent execution on its growth plans, even as some price targets, including the DKK 12 adjustment flagged by JPMorgan, are recalibrated.
DEMANT
DKK 178.70
Demant
7D
-5.6%
1Y
-31.5%

DEMANT: Recent Rating Upgrade May Support Future Upside Despite Softer Margins

The updated analyst price target for Demant has moved slightly lower to about DKK 232 from roughly DKK 238, as analysts balance a modestly higher assumed revenue growth rate against slightly softer margin expectations and a higher discount rate, with recent Street research showing a mix of target cuts from several banks and one upgrade to Buy at DKK 230. Analyst Commentary Recent Street research around Demant reflects a split view, with one Upgrade to Buy around DKK 230 contrasting with several lower price targets and at least one downgrade.
HLUN B
DKK 39.32
H. Lundbeck
7D
-2.0%
1Y
-2.2%

HLUN B: Positive Neuroscience Pipeline Data Will Support Constructive Medium Term Outlook

Analysts have trimmed their DKK price target on H. Lundbeck from about DKK 47.05 to DKK 44.95, citing updated assumptions for revenue growth, profit margins, as well as a slightly higher future P/E multiple and discount rate.
ALK B
DKK 215.00
ALK-Abelló
7D
-1.4%
1Y
36.3%
GUBRA
DKK 331.60
Gubra
7D
-12.0%
1Y
-49.0%
BAVA
DKK 196.75
Bavarian Nordic
7D
1.5%
1Y
13.2%

BAVA: Share Buybacks And Latin America Vaccine Deal Will Support Upside

Analysts now keep their DKK 250 price target for Bavarian Nordic intact, as slightly higher discount and future P/E assumptions together with a modestly stronger profit margin view offset softer revenue growth expectations. What's in the News Bavarian Nordic issued earnings guidance for fiscal 2026, indicating expected revenue in the range of DKK 5,000 million to DKK 5,200 million (Corporate guidance).
COLO B
DKK 488.80
Coloplast
7D
0.8%
1Y
-39.2%

COLO B: Reset P/E And Dividend Will Support Future Upside

Analysts have trimmed their fair value estimate for Coloplast from DKK 678.22 to DKK 615.06, reflecting recent price target cuts and updated assumptions on the discount rate, revenue growth, profit margins and future P/E multiples. Analyst Commentary Recent Street research on Coloplast has focused on recalibrating expectations rather than fundamentally changing the story.
PEG
DKK 0.098
Pharma Equity Group
7D
2.5%
1Y
-29.9%
SMSMED
DKK 3.78
Scandinavian Medical Solutions
7D
5.0%
1Y
-29.7%

Sentiment Still Eluding Scandinavian Medical Solutions A/S (CPH:SMSMED)

Jan 27
Sentiment Still Eluding Scandinavian Medical Solutions A/S (CPH:SMSMED)
VIRO
DKK 12.15
ViroGates
7D
0.8%
1Y
27.2%
STRAP
DKK 624.00
Strategic Partners
7D
11.0%
1Y
-21.2%
MONSO
DKK 0.15
Monsenso
7D
16.7%
1Y
-44.2%